Rotavirus gastroenteritis (RVGE) is an infection which affect children under 5 years and it accounts for up to 50 % the hospitalizations due to diarrhea. Rotarix is two-dose vaccine developed by GlaxoSmithKline (GSK) biologicals which is one of leading vaccines manufacture in the world. Rotarix has launched in 61 countries and over 14 million of doses have been distributed.
Rotarix has shown up to 100 % protection of infants from Rotavirus gastroenteritis in clinical studies involving over 70,000 infants. In Europe the Rotarix has been approved to give infants form six weeks. Philippines, Singapore and Thailand were the first to approve this vaccine Asian region. 90% of deaths of children (total death in previous studies, 611,000 children/year) are occurred in Asian and African region due to Rotavirus gastroenteritis (RVGE). This new introduction will save many deaths and even 94 % of hospitalizations.